Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Minster Pharmaceuticals has completed enrollment in its Phase IIb Tempus study of tonabersat in the preventive treatment of migraine.
Subscribe to our email newsletter
The results of this 500 patient study, which is taking place at specialist and general centres in the US and Canada, are expected in the first quarter of 2009. The primary endpoint of the study, which is placebo controlled, is the reduction in the number of migraine attacks that patients suffer during the last eight weeks of a 20 week treatment period.
The Tempus study is said to have attracted the attention of many of the key opinion leaders in migraine in North America, where the requirement for an effective, preventive treatment for migraine is increasingly recognized. The study’s principal investigator is Richard Lipton, professor of Neurology at the Albert Einstein College of Medicine in New York.
Paul Sharpe, Minster Pharmaceuticals’s CEO, said: “We are delighted to have reached full enrolment in our Tempus study of tonabersat in the prevention of migraine. We believe that around 30% of migraineurs would benefit from an effective and well tolerated treatment for the prevention of migraine, representing a very substantial commercial market.”